Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancers 1

Interventions

Cyclophosphamide 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 6Bortezomib 6tanespimycin 5romidepsin 5Vorinostat 5Tacrolimus 5Magnetic Resonance Spectroscopy 5Gemcitabine 5fludarabine 4Radiotherapy 4Lenalidomide 4Etoposide 4belinostat 3Whole-Body Irradiation 3Specimen Handling 3Nivolumab 3Mycophenolic Acid 3Irinotecan 3Doxorubicin 3Dasatinib 3Brentuximab Vedotin 3Biopsy 3Bendamustine Hydrochloride 3sodium-iodide symporter 2pembrolizumab 2nelarabine 2mogamulizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Mycosis Fungoides × 10-propargyl-10-deazaaminopterin × Clear all
NCT00554827 2020-01-03

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
55 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡